Geode Capital Management LLC Has $2.21 Million Position in NeuroPace, Inc. (NASDAQ:NPCE)

Geode Capital Management LLC boosted its holdings in shares of NeuroPace, Inc. (NASDAQ:NPCE) by 8.7% in the third quarter, according to its most recent filing with the SEC. The firm owned 317,192 shares of the company’s stock after acquiring an additional 25,330 shares during the period. Geode Capital Management LLC’s holdings in NeuroPace were worth $2,211,000 as of its most recent filing with the SEC.

Several other institutional investors and hedge funds also recently made changes to their positions in the business. Millennium Management LLC lifted its stake in NeuroPace by 13.3% in the second quarter. Millennium Management LLC now owns 686,037 shares of the company’s stock valued at $5,186,000 after buying an additional 80,324 shares during the period. Bank of New York Mellon Corp bought a new stake in NeuroPace in the second quarter valued at approximately $257,000. Acadian Asset Management LLC raised its holdings in NeuroPace by 46.0% in the second quarter. Acadian Asset Management LLC now owns 68,918 shares of the company’s stock worth $520,000 after purchasing an additional 21,703 shares during the period. Barclays PLC boosted its position in shares of NeuroPace by 346.0% during the third quarter. Barclays PLC now owns 20,633 shares of the company’s stock worth $144,000 after purchasing an additional 16,007 shares in the last quarter. Finally, Rhumbline Advisers acquired a new position in NeuroPace in the second quarter valued at about $111,000. Institutional investors own 78.83% of the company’s stock.

NeuroPace Price Performance

Shares of NPCE opened at $12.42 on Wednesday. The company has a 50 day moving average of $10.03 and a 200-day moving average of $8.13. The company has a quick ratio of 4.77, a current ratio of 5.59 and a debt-to-equity ratio of 6.03. The stock has a market capitalization of $370.71 million, a P/E ratio of -12.42 and a beta of 2.02. NeuroPace, Inc. has a twelve month low of $5.45 and a twelve month high of $18.15.

NeuroPace (NASDAQ:NPCE) last posted its quarterly earnings data on Tuesday, November 12th. The company reported ($0.19) EPS for the quarter, topping analysts’ consensus estimates of ($0.26) by $0.07. The company had revenue of $21.06 million during the quarter, compared to the consensus estimate of $19.33 million. NeuroPace had a negative net margin of 36.74% and a negative return on equity of 205.41%. During the same period in the prior year, the business posted ($0.28) EPS. As a group, equities research analysts forecast that NeuroPace, Inc. will post -1 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of equities research analysts have recently commented on NPCE shares. Wells Fargo & Company dropped their price target on NeuroPace from $15.00 to $13.00 and set an “overweight” rating on the stock in a research report on Wednesday, November 13th. JPMorgan Chase & Co. raised their price objective on shares of NeuroPace from $9.00 to $14.00 and gave the stock an “overweight” rating in a report on Tuesday, December 17th. One analyst has rated the stock with a hold rating and five have given a buy rating to the company’s stock. Based on data from MarketBeat, NeuroPace presently has a consensus rating of “Moderate Buy” and an average price target of $15.00.

Insider Buying and Selling at NeuroPace

In related news, major shareholder Ltd. Kck sold 223,991 shares of the firm’s stock in a transaction dated Friday, October 25th. The shares were sold at an average price of $5.45, for a total value of $1,220,750.95. Following the completion of the sale, the insider now directly owns 5,270,845 shares in the company, valued at approximately $28,726,105.25. This trade represents a 4.08 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Insiders sold a total of 246,239 shares of company stock worth $1,363,038 over the last ninety days. 22.20% of the stock is currently owned by corporate insiders.

NeuroPace Company Profile

NeuroPace, Inc operates as a medical device company in the United States. The company develops RNS system, a brain-responsive neuromodulation system that delivers personalized, real-time treatment at the seizure source for treating medically refractory focal epilepsy. It also records continuous brain activity data and enables clinicians to monitor patients in person and remotely.